CCA
STOK icon

Cygnus Capital Advisors’s Stoke Therapeutics STOK Stock Holding History

Cygnus Capital Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,500
Closed -$49K – 104
2026
Q1 		$49K Sell
1,500
-1,500
-50% -$49.2K 0.03% 74
2025
Q4 		$95K Buy
+3,000
New +$90.2K 0.07% 60

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cygnus Capital Advisors's STOK Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 1,500 shares — an estimated $49K sold.

Cygnus Capital Advisors first reported a position in STOK in Q4 2025 and held it in 2 quarters. The position peaked at $95K in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 1,500 Stoke Therapeutics shares in Q2 2026, an estimated $49K.
  • Cygnus Capital Advisors first reported a position in Stoke Therapeutics in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's Stoke Therapeutics position peaked at $95K in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.